Flex Pharma, Inc. Contracts & Agreements

Separation and Release Agreement, dated February 20, 2024, by and between Salarius Pharmaceuticals, Inc. and David J. Arthur (Filed With SEC on February 23, 2024)

Consulting Agreement, dated February 20, 2024, by and between Salarius Pharmaceuticals, Inc. and David J. Arthur (Filed With SEC on February 23, 2024)

Notice of Stock Option Amendment, dated February 20, 2024, by and between Salarius Pharmaceuticals, Inc. and David J. Arthur (Filed With SEC on February 23, 2024)

Indemnification Agreement, dated February 20, 2024, by and between Salarius Pharmaceuticals, Inc. and David J. Arthur (Filed With SEC on February 23, 2024)

Amendment to Executive Employment Agreement, dated February 20, 2024, by and between Salarius Pharmaceuticals, Inc. and Mark J. Rosenblum (Filed With SEC on February 23, 2024)

Amended and Restated Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan (Filed With SEC on June 15, 2023)

Form of Common Stock Warrants (Filed With SEC on May 16, 2023)

Form of Pre-Funded Warrants (Filed With SEC on May 16, 2023)

Form of Placement Agent Warrants (Filed With SEC on May 16, 2023)

Form of Securities Purchase Agreement (Filed With SEC on May 16, 2023)

Form of Registration Rights Agreement (Filed With SEC on May 16, 2023)

Form of Warrant (Filed With SEC on April 22, 2022)

Securities Purchase Agreement dated April 22, 2022 (Filed With SEC on April 22, 2022)

Form of Voting Agreement (Filed With SEC on April 22, 2022)

Acquisition and Strategic Collaboration Agreement, dated January 12, 2022 (Filed With SEC on January 13, 2022)

Form of Warrant (Filed With SEC on July 1, 2021)

Description of Registrant's Securities (Filed With SEC on March 18, 2021)

Underwriting Agreement, March 4, 2021, between Salarius Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc., as representative of the several underwriters (Filed With SEC on March 8, 2021)

At the Market Offering Agreement, dated February 5, 2021, by and among Salarius Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on February 5, 2021)

Form of Inducement Warrant (Filed With SEC on December 11, 2020)

Form of Inducement Letter (Filed With SEC on December 11, 2020)

Underwriting Agreement, July 30, 2020, between Salarius Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc., as representative of the several underwriters (Filed With SEC on August 3, 2020)

Salarius Pharmaceuticals, Inc., 2015 Equity Incentive Plan, as amended (Filed With SEC on June 19, 2020)

Salarius Pharmaceuticals, Inc., 2015 Employee Stock Purchase Plan, as amended (Filed With SEC on June 19, 2020)

Employment Agreement between Mark J. Rosenblum and Salarius Pharmaceutical, Inc., dated April 24, 2020 (Filed With SEC on April 29, 2020)

Description of Registrants Securities (Filed With SEC on March 23, 2020)

Separation and Release Agreement between Scott Jordan and the Registrant, dated March 18, 2020 (Filed With SEC on March 23, 2020)

Consulting Agreement between Bruce McCreedy and the Registrant, dated March 6, 2020 (Filed With SEC on March 23, 2020)

Underwriting Agreement, dated February 7, 2020, between Salarius Pharmaceuticals, Inc. and Ladenburg Thalmann & Co. Inc., as representative of the several underwriters (Filed With SEC on February 12, 2020)

Common Stock Purchase Warrant dated February 11, 2020 (Filed With SEC on February 12, 2020)

Form of Underwriting Agreement (Filed With SEC on February 6, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on February 6, 2020)

Form of Preferred Stock Certificate of Registrant (Filed With SEC on February 6, 2020)

Form of Underwriting Agreement (Filed With SEC on January 28, 2020)

Form of Common Stock Purchase Warrant (Filed With SEC on January 28, 2020)

Registration Rights Agreement, dated October 24, 2019, between Salarius Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 28, 2019)

Common Stock Purchase Agreement, dated October 24, 2019 between Salarius Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 28, 2019)

Offer of Employment with Salarius Pharmaceuticals, Inc. dated as of September 10, 2019, by and between Salarius Pharmaceuticals, Inc. and Mark Rosenblum (Filed With SEC on September 16, 2019)

Amendment to Second Amended and Restated Executive Employment Agreement dated as of September 10, 2019, by and among Salarius Pharmaceuticals, Inc., Salarius Pharmaceuticals, LLC,... (Filed With SEC on September 16, 2019)

Amendment to Amended and Restated Executive Employment Agreement dated as of September 10, 2019, by and among Salarius Pharmaceuticals, Inc., Salarius Pharmaceuticals, LLC, and... (Filed With SEC on September 16, 2019)

Asset Purchase Agreement dated July 23, 2019 by and among Salarius Pharmaceuticals, Inc., Flex Innovation Group LLC and Cliff-Cartwright Corporation (Filed With SEC on July 24, 2019)

Waiver No. 1 to the Agreement and Plan of Merger dated July 18, 2019 by and among Flex Pharma, Inc., Falcon Acquisition Sub, LLC, and Salarius Pharmaceuticals, LLC (Filed With SEC on July 22, 2019)

Form of Indemnification Agreement between the Registrant and its directors and officers (Filed With SEC on July 22, 2019)

Amendment No. 1 to Agreement and Plan of Merger dated June 27, 2019 by and among Flex Pharma, Inc., Falcon Acquisition Sub, LLC, and Salarius Pharmaceuticals, LLC (Filed With SEC on July 1, 2019)

Exclusive License Agreement, dated August 3, 2011, between the University of Utah Research Foundation and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Exclusive Pharmaceutical Sublicense Agreement, dated November 25, 2016, between HLB LifeScience Co., Ltd. and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Cancer Research Grant Contract, dated June 1, 2016, between the Cancer Prevention and Research Institute of Texas and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Patent and Know How Exclusive License Agreement, dated December 18, 2018, between NuPotential, Inc., and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Amended and Restated Executive Employment Agreement, dated February 5, 2019, between David J. Arthur and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Second Amended and Restated Executive Employment Agreement, dated February 6, 2019, between Scott Jordan and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Manager Agreement, dated January 21, 2017, between Jonathan P. Northrup and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Manager Agreement, dated January 21, 2017, between Sunil Sharma and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Restricted Unit Award Agreement, dated August 1, 2016, between David J. Arthur and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Restricted Unit Award Agreement, dated January 21, 2017, between Scott Jordan and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Restricted Unit Award Agreement, dated January 21, 2017, between Jonathan P. Northrup and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Restricted Unit Award Agreement, dated January 21, 2017, between Sunil Sharma and Salarius Pharmaceuticals, LLC (Filed With SEC on February 14, 2019)

Royalty Agreement, dated January 2019, by and among Flex Innovation Group LLC, Bruce Bean, Donald MacKinnon, Roderick MacKinnon and Christoph Westphal (Filed With SEC on February 14, 2019)

Voting Agreement between Salarius Pharmaceuticals, LLC, Flex Pharma, Inc. and William K. McVicar (Filed With SEC on January 4, 2019)

Voting Agreement between Flex Pharma, Inc., Salarius Pharmaceuticals, LLC and David J. Arthur (Filed With SEC on January 4, 2019)

Lock-up Agreement for the benefit of Salarius Pharmaceuticals, LLC executed by William K. McVicar (Filed With SEC on January 4, 2019)

Lock-up Agreement for the benefit of Salarius Pharmaceuticals, LLC executed by David J. Arthur (Filed With SEC on January 4, 2019)

Agreement and Plan of Merger dated January 3, 2019 by and among Flex Pharma, Inc., Falcon Acquisition Sub, LLC, and Salarius Pharmaceuticals, LLC (Filed With SEC on January 4, 2019)

Amendment to Executive Employment Agreement, effective as of June 20, 2018, by and between the Registrant and William McVicar (Filed With SEC on August 1, 2018)

Amendment to Executive Employment Agreement, effective as of June 20, 2018, by and between the Registrant and John McCabe (Filed With SEC on August 1, 2018)

Separation Agreement, effective as of June 26, 2018, by and between the Registrant and Thomas Wessel (Filed With SEC on August 1, 2018)

Advisor Agreement, dated June 26, 2018, by and between the Registrant and Thomas Wessel (Filed With SEC on August 1, 2018)

Amendment to Offer Letter, effective as of January 8, 2018, by and between the Company and Thomas Wessel (Filed With SEC on January 12, 2018)

Amended and Restated Executive Employment Agreement, effective as of August 1, 2017, by and between the Registrant and William McVicar (Filed With SEC on November 6, 2017)

AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on July 11, 2017)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on April 5, 2017)

FLEX PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY AS REVISED ON JANUARY 18, 2017 (Filed With SEC on March 8, 2017)

PRUDENTIAL CENTER PRUDENTIAL TOWER 800 BOYLSTON STREET BOSTON, MASSACHUSETTS Lease Dated January 27, 2017 (Filed With SEC on February 2, 2017)

FLEX INNOVATION GROUP LLC ADVISOR AGREEMENT Date: August 24, 2016 (Filed With SEC on November 2, 2016)

SUPPLY AGREEMENT (Filed With SEC on August 3, 2016)

LICENSE AGREEMENT (Filed With SEC on August 3, 2016)

PRODUCTION AGREEMENT (Filed With SEC on May 4, 2016)

Prudential Tower 800 Boylston Street Floor 24 Boston, MA 02199 www.flex-pharma.com (Filed With SEC on March 8, 2016)

LICENSE AGREEMENT (Filed With SEC on March 8, 2016)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 8, 2016)

LICENSE AGREEMENT (Filed With SEC on November 4, 2015)

1 EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on September 9, 2015)

FLEX PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY AS REVISED ON JUNE 29, 2015 (Filed With SEC on August 5, 2015)

EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2015)

FLEX PHARMA, INC. 2015 EQUITY INCENTIVE PLAN OPTION AGREEMENT (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) (Filed With SEC on March 24, 2015)

[ ] Flex Pharma, Inc. Common Shares UNDERWRITING AGREEMENT (Filed With SEC on January 20, 2015)

LICENSE AGREEMENT (Filed With SEC on January 20, 2015)

FLEX PHARMA, INC. INDEMNITY AGREEMENT (Filed With SEC on January 13, 2015)

FLEX PHARMA, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [ ], 2015 APPROVED BY THE STOCKHOLDERS: [ ], 2015 IPO DATE: [ ], 2015 (Filed With SEC on January 13, 2015)

FLEX PHARMA, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [ ], 2015 APPROVED BY THE STOCKHOLDERS: [ ], 2015 (Filed With SEC on January 13, 2015)

FLEX PHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on January 13, 2015)

AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on December 29, 2014)

FLEX PHARMA, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 21, 2014 APPROVED BY THE STOCKHOLDERS: MARCH 21, 2014 AMENDED BY THE BOARD OF DIRECTORS:... (Filed With SEC on December 29, 2014)

Exhibit A (Filed With SEC on December 29, 2014)

Prudential Tower 800 Boylston Street Floor 24 Boston, MA 02199 VOX 617-874-182 www.flex-pharma.com (Filed With SEC on December 29, 2014)

ROYALTY AGREEMENT (Filed With SEC on December 29, 2014)

FOUNDERS AGREEMENT (Filed With SEC on December 29, 2014)

TECHNOLOGY ASSIGNMENT AGREEMENT (Filed With SEC on December 29, 2014)

PATENT ASSIGNMENT AGREEMENT (Filed With SEC on December 29, 2014)

SUBLEASE (Filed With SEC on December 29, 2014)

LICENSE AGREEMENT (Filed With SEC on December 29, 2014)

Category

Industry

Companies

Contracts

Flex Pharma, Inc. Contracts & Agreements